Legal Opinion
United States Ex Rel. Petratos v. Genentech Inc.
Court of Appeals for the Third Circuit
Decided May 1, 2017No. 15-3805PublishedCited by 127 opinions
1Opinion of the Court
OPINION OF THE COURT
HARDIMAN, Circuit Judge.
This appeal arising under the False Claims Act involves a multi-billion dollar cancer drug, Avastin, which was developed by Appellee Genentech. Relator Gerasimos Petratos, who was head of healthcare data analytics for Genentech, filed a qui tam action soon after leaving the company. He alleged that Genentech suppressed data that caused doctors to certify incorrectly that Avastin was “reasonable and necessary” for certain at-risk Medicare patients. The District Court dismissed Petratos’s suit for failure to state a claim. Although we disagree with…
2Cases cited26 opinions
- United States Ex Rel. Marcus v. HessSupreme Court of the United States · 1943
- Universal Health Services, Inc. v. United States ex rel. EscobarSupreme Court of the United States · 2016
- Paroline v. United StatesSupreme Court of the United States · 2014
- United States Ex Rel. Schumann v. Astrazeneca Pharmaceuticals L.P.Court of Appeals for the Third Circuit · 2014
- United States of America, Ex Rel. Richard Williams v. Martin-Baker Aircraft Company, Ltd.Court of Appeals for the D.C. Circuit · 2005
21 more not listed; retrieve them via the Exa API.
3Cited by127 opinions
- United States Ex Rel. Campie v. Gilead Sciences, Inc.Court of Appeals for the Ninth Circuit · 2017
- United States Ex Rel. Jane Doe v. Heart Solution, PCCourt of Appeals for the Third Circuit · 2019
- United States Ex Rel. Spay v. CVS Caremark Corp.Court of Appeals for the Third Circuit · 2017
- United States Ex Rel. Harman v. Trinity Industries Inc.Court of Appeals for the Fifth Circuit · 2017
- Victoria Druding v. Care AlternativesCourt of Appeals for the Third Circuit · 2020
122 more not listed; retrieve them via the Exa API.